Coronavirus information from UCLA and UCLA Health.

CDR3 develops stem cell-based immunotherapies to cure HPV-related cancers using chimeric antigen receptors or chronic viral infections using T cell receptors.

Market:

Today, we lack cures for most virus-related cancers and chronic viral infections, especially from human papillomavirus, or HPV, and cytomegalovirus, or CMV, which can be fatal for those with weakened immune systems. CDR3’s stem cell-based treatments target HPV-associated cancers, a $16.3B market in 2018 growing at 4.5% yearly, and chronic viral infections, a rapidly growing market estimated to reach $44.2B by 2026 — with chronic CMV alone a $1.2B market in 2020 growing at 12.3% yearly.


Technology:

CDR3’s patented technology alters blood stem cells to add chimeric antigen receptors (CARs) or T cell receptors (TCRs) that enable the body’s natural defenses to target virus-associated cancers. These stem cells engraft in bone marrow and develop, normally and continuously, into T cells. Isolating a patient’s own cells and infusing the CAR/TCR gene therapy creates a permanent source of T cells expressing the CAR/TCR, avoiding the high cost and significant limitations of current T cell therapy approaches.


Advantages:

  • Stem cell-based approach
  • Limited manipulation and cell expansion
  • Long-term engraftment
  • Cells develop naturally in the body
  • Produces persistent, functional T cells

Development Stage:

  • Pre-clinical

IP Protection:

  1. US 9,228,007 B1 - RECOMBINANT HUMAN PROGENITOR CELLS, ENGINEERED HUMAN THYMOCYTES, AND ENGINEERED HUMAN T CELLS, issued January 5, 2016
  2. US 9,951,118 B2 - ENGINEERING ANTIVIRAL T CELL IMMUNITY THROUGH STEM CELLS AND CHIMERIC ANTIGEN RECEPTORS, issued April 24, 2018
  3. US 2020/0061117 A1 - PROTECTIVE CHIMERIC ANTIGEN RECEPTOR STEM CELL GENE THERAPY FOR VIRAL INFECTION, filed May 4, 2018
  4. PCT/US2020/055 1 94 - CHIMERIC ANTIGEN RECEPTORS AGAINST HUMAN CYTOMEGALOVIRUS, priority date October 11, 2019

Select Publications:

  • Cancer-fighting gene immunotherapy shows promise as treatment for HIV. Artificial receptors kill cells infected with the virus that causes AIDS, UCLA study finds. Enrique Rivero, July 14, 2016
  • Gene therapy using CAR T cells could provide long-term protection against HIV. UCLA RESEARCH ALERT, Enrique Rivero, January 25, 2018
  • Researchers devise more efficient, enduring CAR gene therapy to combat HIV. Enrique Rivero, Thursday, April 1, 2021
  • CIRM funding helps improve immune cell therapy to combat HIV. APRIL 7, 2021, YIMY VILLA
  • Novel CAR T cell therapy to Treat HIV, posted on LinkedIn Cell Immunotherapy user group in August, 2021

Contact:

Website: cdr3therapeutics.com
Phone: 925-765-8205 Email: matt@lorence.tech LinkedIn
Others